Genetic Study of Families With High Frequency of Hodgkin Lymphoma

Status Completed

Clinical Trial Summary

Hodgkin lymphoma (HL) is a relatively rare disorder with known familiar aggregation (i.e. HL in more than one child, or parent and child). Because affected individuals in familial HL are genetically related, the existence of such families has long been considered as evidence in support of a genetic basis of HL susceptibility. However, it is largely unknown which genetic variations are responsible for recurring HL in families. Because the effects of genetic variants are likely to be strong in familial HL, identification of such variations will potentially reveal biological pathways critical to the pathogenesis of HL.

PRIMARY OBJECTIVE:

- To perform genome-wide sequencing of families with recurring Hodgkin lymphoma cases (affected as well as non-affected family members) to identify potential disease-causing germline genetic variations.

SECONDARY OBJECTIVE:

- To describe demographic and clinical features of the affected families.

Clinical Trial Description

This study entails a clinical interview and submission of a peripheral blood or saliva sample for non-tumor DNA. Participants diagnosed with HL at outside institutions will be requested to sign a release form to allow the outside institution to send their pathology report confirming their HL diagnosis. If available, previously banked tumor tissue samples will be utilized to assess genetic alterations related to HL. Detailed history will be obtained (e.g., demographics, environmental exposures, cancer risk factors, and family pedigree) to facilitate the analysis of phenotype-genotype correlations, taking into account potential confounding factors.

Investigators will examine the germline and possibly the tumor DNA of each individual participant and use the data from all participants to determine if a gene change is related to HL. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02795013
Study type	Observational
Source	St. Jude Children's Research Hospital
Contact
Status	Completed
Phase
Start date	August 17, 2016
Completion date	February 27, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05400122` - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer	Phase 1
Completed	`NCT01947140` - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies	Phase 1/Phase 2
Recruiting	`NCT05019976` - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma	N/A
Active, not recruiting	`NCT03617666` - Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study	Phase 2
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer
Recruiting	`NCT02507479` - Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies	Phase 2
Active, not recruiting	`NCT02191930` - Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma	Phase 2
Completed	`NCT01943682` - Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma	Phase 1
Completed	`NCT01393106` - Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma	Phase 2
Terminated	`NCT00992030` - R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma	Phase 3
Terminated	`NCT00722865` - Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma	Phase 2
Unknown status	`NCT00598624` - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)	Phase 2
Completed	`NCT03242902` - To Decrease Fatigue With Light Therapy	Phase 3
Active, not recruiting	`NCT05205512` - Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial	N/A
Recruiting	`NCT03681561` - Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT03250962` - SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma	Phase 2
Recruiting	`NCT04510610` - Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma	Phase 2/Phase 3
Completed	`NCT06295211` - Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
Active, not recruiting	`NCT02256137` - A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
Completed	`NCT02432235` - Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma	Phase 1